If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

  • There is currently no data for MSYS

Company Update

25 Jun 2024 08:06

RNS Number : 7571T
Microsaic Systems plc
25 June 2024
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

FOR IMMEDIATE RELEASE

 

 

Microsaic Systems plc

 

("Microsaic" or the "Company")

Company update

 

Microsaic Systems plc (AIM: MSYS), the developer of microelectronic instruments and provider of integrated Modern Water analytical solutions, is pleased to announce the following update.

 

Research & Development Tax Credit

 

The Company is also pleased to announce it has now received a research and development tax credit from HMRC in the amount of £262,000 for qualifying costs expended in 2022. These costs primarily relate to research and development work by the Company on the pathogen detector for identifying Covid-19 in water. As previously announced, the Company is further developing a device to identify and monitor a wide range of pathogens in water, by adapting the Covid-19 model into an online multi-pathogen detector capable of delivering rapid results.

 

Business Restructuring

 

Having restructured the business at the turn of the year, the Board remains committed to the Company's reset objectives starting this year and to applying a business plan built on the integration of the Microsaic Systems and Modern Water technologies. This technical integration for water testing services is now branded and marketed as 'Tethys Purity' to reflect the broad and comprehensive water testing capabilities that the Company can now offer. Tethys Purity is a modular concept where customers can select the entire suite or a range of devices and services to meet their specific needs, from PFAS detection to toxic water monitoring including pathogen identification. The Company is actively building up partnerships and joint ventures to support its commercial objectives to deliver a total solution for water testing and safety.

 

Bob Moore, Acting Executive Chairman of Microsaic, commented:

 

"We are moving the Company forward by building on our newly combined technologies and enhanced business capabilities. We look forward to completing our worthwhile projects as part of our wider objective of growth and business development, and to building mutually rewarding partnerships to create value for our investors."

 

 

Microsaic Systems plc

Bob Moore, Acting Executive Chairman

+44 (0) 20 3657 0050

via TPI

 

 

Singer Capital Markets (Nominated Adviser)

Aubrey Powell / Oliver Platts

+44 (0)20 7496 3000

 

 

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

 

About Microsaic Systems and Modern Water

Microsaic is highly experienced in microelectronics and development of instrumentation. Having acquired the Modern Water business it has reset, diversified and widened its capabilities into broader based analytical equipment supply and services company with combined technologies resulting in comprehensive water testing capabilities. The Company has an extensive existing and newly acquired innovative patent portfolio in industry-leading technology designed and developed for "Industry 4.0" application serving markets in diversified Industries, Human and Environmental Health. Microsaic's micro-mass spectrometer system and water testing solutions enables analytical detection and characterisation at the point-of-need, whether within a mobile testing capability, conventional laboratory setting, or within a bioprocessing facility for continuous detection of data at multiple steps in the process workflow.

 

Microsaic's products and solutions are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point-of-need applications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUVRBRSSUNURR
Date   Source Headline
4th Jun 20217:00 amRNSPre-Annual General Meeting Q&A
25th May 20217:00 amRNSDevelopment of PFAS detection platform
20th May 20217:00 amRNSPosting of Annual Report and Notice of AGM
4th May 20219:00 amRNSPrice Monitoring Extension
4th May 20217:01 amRNSHeads of Terms signed for Chinese market
4th May 20217:00 amRNSFinal Results
28th Apr 20217:00 amRNSNotice of Results and Investor Presentation
31st Mar 20214:41 pmRNSSecond Price Monitoring Extn
31st Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20217:00 amRNSFramework Services Agreement Update
9th Mar 20212:52 pmRNSHolding(s) in Company
9th Mar 20212:06 pmRNSSecond Price Monitoring Extn
9th Mar 20212:01 pmRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSHolding(s) in Company
3rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
3rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Feb 20212:13 pmRNSHolding(s) in Company
16th Feb 20219:00 amRNSPrice Monitoring Extension
15th Feb 20217:00 amRNSFramework Services Agreement
9th Feb 20219:05 amRNSSecond Price Monitoring Extn
9th Feb 20219:00 amRNSPrice Monitoring Extension
8th Feb 20215:59 pmRNSHolding(s) in Company
8th Feb 20215:58 pmRNSHolding(s) in Company
8th Feb 202111:08 amRNSHolding(s) in Company
8th Feb 202111:06 amRNSSecond Price Monitoring Extn
8th Feb 202111:00 amRNSPrice Monitoring Extension
8th Feb 20219:05 amRNSSecond Price Monitoring Extn
8th Feb 20219:00 amRNSPrice Monitoring Extension
5th Feb 20215:02 pmRNSHolding(s) in Company
5th Feb 20213:22 pmRNSHolding(s) in Company
5th Feb 20218:05 amRNSDirector/PDMR Shareholding
5th Feb 20218:01 amRNSBoard Changes
4th Feb 202110:22 amRNSResult of General Meeting
29th Jan 20212:05 pmRNSSecond Price Monitoring Extn
29th Jan 20212:00 pmRNSPrice Monitoring Extension
22nd Jan 20215:26 pmRNSFull Exercise of Broker Option
19th Jan 20212:06 pmRNSSecond Price Monitoring Extn
19th Jan 20212:00 pmRNSPrice Monitoring Extension
19th Jan 202111:05 amRNSSecond Price Monitoring Extn
19th Jan 202111:00 amRNSPrice Monitoring Extension
19th Jan 20219:05 amRNSSecond Price Monitoring Extn
19th Jan 20219:00 amRNSPrice Monitoring Extension
19th Jan 20217:00 amRNSFundraising, Board Changes and Notice of GM
6th Jan 20214:41 pmRNSSecond Price Monitoring Extn
6th Jan 20214:36 pmRNSPrice Monitoring Extension
6th Jan 20212:05 pmRNSSecond Price Monitoring Extn
6th Jan 20212:00 pmRNSPrice Monitoring Extension
6th Jan 20217:00 amRNSStatement re. share price movement
22nd Dec 20204:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.